Reply
Marie Sinclair, Brooke Chapman, Rudolf Hoermann, Peter W. Angus, Adam Testro, Thomas Scodellaro, Paul J. Gow – 13 December 2019
Marie Sinclair, Brooke Chapman, Rudolf Hoermann, Peter W. Angus, Adam Testro, Thomas Scodellaro, Paul J. Gow – 13 December 2019
Max N. Brondfield, Jennifer L. Dodge, Ryutaro Hirose, Julie Heimbach, Francis Y. Yao, Neil Mehta – 13 December 2019 – For patients with hepatocellular carcinoma (HCC) listed for liver transplantation (LT), United Network for Organ Sharing (UNOS) enacted policy changes in 2015 to improve equity between HCC and non‐HCC patients. We evaluated the impact of these changes on regional disparities in wait‐list dropout and LT.
Maria Eugenia Guicciardi, Christy E. Trussoni, Nicholas F. LaRusso, Gregory J. Gores – 13 December 2019 – Cholangiocytes are the target of a group of chronic liver diseases termed the “cholangiopathies,” in which cholangiocytes react to exogenous and endogenous insults, leading to disease initiation and progression.
Use of cannabis is growing in the population with increased interest in potential medicinal use as well as recreational use depending on the jurisdiction. Given this, clinicians need to have an understanding about cannabis and its potential impacts on liver disease. This webinar will provide attendees information about cannabis, its major components (THC/CBD) as well as discuss potential policy implications regarding transplantation.
Christophe Bureau, Jean Pierre Vinel, Olivier Lairez – 12 December 2019
Marc G. Ghany, Timothy R. Morgan, AASLD‐IDSA Hepatitis C Guidance Panel – 9 December 2019
Marc G. Ghany, Timothy R. Morgan, AASLD‐IDSA Hepatitis C Guidance Panel – 9 December 2019
Zhixiang Hu, Liangqing Dong, Shengli Li, Zhe Li, Yejun Qiao, Yuchen Li, Jie Ding, Zhiao Chen, Yangjun Wu, Zhen Wang, Shenglin Huang, Qiang Gao, Yingjun Zhao, Xianghuo He – 9 December 2019
Kedar Patil, Amanda Ricciuto, Alaa Alsharief, Jehan Al‐Rayahi, Afsaneh Amirabadi, Peter C. Church, Binita M. Kamath, Mary‐Louise C. Greer – 6 December 2019 – Magnetic resonance cholangiopancreatography (MRCP) has not been assessed as a surrogate biomarker in pediatrics. We aimed to determine the inter‐rater reliability, prognostic utility, and construct validity of the modified Majoie endoscopic retrograde cholangiopancreatography classification applied to MRCP in a pediatric primary sclerosing cholangitis (PSC) cohort.
Zhipeng Li, Shaun G. Weller, Kristina Drizyte‐Miller, Jing Chen, Eugene W. Krueger, Bridget Mehall, Jacqueline Stöckli, Carol A. Casey, Hong Cao, Mark A. McNiven – 6 December 2019